摘要
目的系统评价中国耐多药结核的不良治疗结局情况。方法计算机检索CNKI、WanFang Data、CBM、PubMed、EMbase、Web of Science数据库,搜集有关中国耐多药结核不良治疗结局的研究,检索时限均从建库至2021年4月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用Stata 12.0软件进行Meta分析。结果共纳入11个研究,包含4 465例患者。Meta分析结果显示:我国耐多药结核治疗成功率为62%[95%CI(55%,70%)],失败率为19%[95%CI(12%,26%)],丢失率为7%[95%CI(4%,10%)],死亡率为6%[95%CI(4%,8%)],总体不良结局率为25%[95%CI(19%,32%)]。结论现有有限证据表明,我国耐多药结核治疗失败率较高。受纳入研究数量和质量限制,上述结论尚待更多高质量研究予以验证。
Objective To systematically review the unfavorable treatment outcome of multidrug-resistant tuberculosis in China. Methods CNKI, WanFang Data, CBM, PubMed, EMbase, and Web of Science databases were electronically searched to collect studies that reported unfavorable treatment outcomes of multidrug-resistant tuberculosis in China from inception to April 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Meta-analysis was then performed by using Stata 12.0 software. Results A total of 11 studies involving 4 465 patients were included. The results of meta-analysis showed that the overall rate of treatment success was 62%(95%CI 55% to 70%), the rate of treatment failure was 19%(95%CI 12% to 26%), the rate of default was7%(95%CI 4% to 10%), the rate of mortality was 6%(95%CI 4% to 8%) and the rate of unfavorable treatment outcome was 25%(95%CI 19% to 32%). Conclusions Current evidence shows that the treatment failure rate of multidrugresistant tuberculosis in China is slightly high. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.
作者
刘俊萍
孙彦波
张淑兰
关黎
刘智新
孙明雷
赵娟
王晨
邹丹丹
梁立波
LIU Junping;SUN Yanbo;ZHANG Shulan;GUAN Li;LIU Zhixin;SUN Minglei;ZHAO Juan;WANG Chen;ZOU Dandan;LIANG Libo(School of Health Management,Harbin Medical University,Harbin 150081,P.R.China;Heilongjiang Provincial Center for Disease Control and Prevention,Harbin 150030,P.R.China;Infectious Disease Hospital of Heilongjiang Province,Harbin 150500,P.R.China;National Health Social Risk Prevention and Collaboration Innovation Center,Shanghai 200032,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2021年第10期1174-1178,共5页
Chinese Journal of Evidence-based Medicine
基金
国家自然科学基金项目(编号:71974049、71673073)。
关键词
耐多药结核
不良结局
系统评价
META分析
Multidrug-resistant tuberculosis
Unfavorable treatment outcome
Systematic review
Meta-analysis
作者简介
通信作者:梁立波,Email:llbhit@163.com。
